Chartwell Investment Partners, LLC Aerie Pharmaceuticals Inc Transaction History

Chartwell Investment Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 29, 2020	SELL	$17.72 - $25.1 $389,840 - $552,200	-22,000 Closed	0 $0
Q3 2019 Oct 29, 2019	SELL	$18.41 - $28.0 $892,590 - $1.36 Million	-48,484 Reduced 68.79%	22,000 $423,000
Q2 2019 Aug 19, 2019	BUY	$28.97 - $48.21 $816,113 - $1.36 Million	28,171 Added 66.58%	70,484 $2.08 Million
Q1 2019 Apr 11, 2019	BUY	$36.32 - $49.25 $674,752 - $914,966	18,578 Added 78.27%	42,313 $2.01 Million
Q4 2018 Feb 01, 2019	BUY	$33.0 - $60.04 $24,222 - $44,069	734 Added 3.19%	23,735 $857,000
Q3 2018 Nov 08, 2018	BUY	$56.15 - $73.9 $1,796 - $2,364	32 Added 0.14%	23,001 $1.42 Million
Q2 2018 Aug 09, 2018	SELL	$47.85 - $70.45 $56,893 - $83,765	-1,189 Reduced 4.92%	22,969 $1.55 Million
Q1 2018 May 08, 2018	BUY	$51.15 - $61.0 $16,419 - $19,581	321 Added 1.35%	24,158 $1.44 Million
Q1 2018 May 08, 2018	SELL	$51.15 - $61.0 $16,419 - $19,581	-321 Reduced 1.33%	23,837 $1.29 Million
Q4 2017 Feb 08, 2018	SELL	$50.85 - $65.1 $72,868 - $93,288	-1,433 Reduced 5.6%	24,158 $1.44 Million
Q3 2017 Nov 08, 2017	BUY	$48.6 - $60.1 $1.24 Million - $1.54 Million	25,591	25,591 $1.24 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.